Internal Medicine, Hematology · New York, NY
NPI
1609884188
Since 2006
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
1275 York Ave
New York, NY, 10065
Phone (212) 639-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
638 services
Medicare patients, 2024
207
Average age 73
Drug cost, 2024
$5.3M
502 prescriptions
Company payments, 2025
$28K
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael J Mauro was code 99215 (office e&m - established), 351 times for 157 patients. In total Michael J Mauro billed 638 services in 10 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-04-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 351 | 157 | $125.27 | $44K |
| 99233 Hospital E&M - Subsequent | Facility | 218 | 31 | $103.90 | $23K |
| 99205 Office E&M - New | Office | 28 | 28 | $160.77 | $4,501 |
By year: 2022 $45K for 560 services; 2023 $51K for 530 services; 2024 $75K for 638 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael J Mauro prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 113 prescriptions and refills. In total Michael J Mauro wrote 502 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 113 | 113 | 21 | $1.4M |
| Hydroxyurea Generic | 100 | 178 | 27 | $2,535 |
| Allopurinol Generic | 57 | 107 | 17 | $663 |
| Scemblix Asciminib Hydrochloride | 54 | 54 | Under 11 | $1.1M |
| Ojjaara Momelotinib Dihydrochloride | 39 | 39 | Under 11 | $1.4M |
| Sprycel Dasatinib | 37 | 37 | Under 11 | $349K |
| Vonjo Pacritinib Citrate | 24 | 24 | Under 11 | $571K |
| Imatinib Mesylate Generic | 17 | 17 | Under 11 | $23K |
| Pegasys Peginterferon Alfa-2a | 16 | 16 | Under 11 | $73K |
| Bosulif Bosutinib | 15 | 15 | Under 11 | $226K |
Brand drugs: 304 claims; generic drugs: 198 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael J Mauro $28K ($26K in general payments such as food, travel and fees and $2,439 for research) from 4 companies. The largest payer was Novartis Pharma AG with $15K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.